Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Clinical Trial
NCT01931839Last updated: 12/3/2025
VRTX
Vertex Pharmaceuticals Incorporated
